Tg Therapeutics

1. BRIUMVI (ublituximab) - supplemental BLA2H 2026BRIUMVI (ublituximab) - supplemental BLA, 2H 2026, material
2. Azer-cel Ph1 interim2H 2026Azer-cel Ph1 interim, 2H 2026, notable
3. Subcutaneous ublituximab Ph3 topline1Q 2027Subcutaneous ublituximab Ph3 topline, 1Q 2027, thesis-defining
4. BRIUMVI (ublituximab) - ENHANCE Ph31Q 2027BRIUMVI (ublituximab) - ENHANCE Ph3, 1Q 2027, major
5. Subcutaneous ublituximab commercial launch2028Subcutaneous ublituximab commercial launch, 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.